Bling®
Fast. Clear. Accurate.
Objective detection made simple
for every child everywhere.
An instant and objective Pass/Refer
readout based on actual brain function,
not just risk factors.
Rebion®
THE WINDOW TO THE BRAIN
Manufactured by
Canon
CANON VIRGINIA, INC.

Direct Detection of Micro-Strabismus and Amblyopia is Now Possible, instead of screening for just risk factors!

Based on years of R&D into new technologies at major medical institutions, Rebion now offers Blinq, the only FDA cleared portable neural performance scanner, that actually detects micro-strabismus and amblyopia. Blinq conducts a 3-second Neural Performance Scan of the fovea to accurately detect binocularity associated with as little as 1-degree misalignment.



Why is Direct Detection so Important?

Clinical studies funded by the NIH/NEI have shown that screening with Blinq is a dramatically more accurate approach to measuring for amblyopia than methods which merely collect data on amblyopic risk factors **(ARF)**.* Greater accuracy leads to a reduction in care costs while improving patient outcomes.

Results from NIH/NEI Funded Study 1

Blinq®

Sensitivity



Specificity



Accuracy

ARF



Sensitivity



Specificity



Accuracy

1.Shah SS, et al. Validation of the Pediatric Vision Scanner in a normal preschool population. Journal of AAPOS. 2021.
2. JAMA Ophthalmol. 2014;132(7):B14-B20. doi10.100/jamaophthalmol2014.424

Neural Performance Scanning (NPS)

Using proprietary retinal polarization scanning to measure bilateral fixation via fibers of the fovea, NPS precisely measures retinal nerve fiber patterns, instantly determining if faulty fixation is present. NPS is cleared by the FDA for screening of micro-strabismus and amblyopia (lazy eye).



Neural Performance Scanning uses proprietary retinal polarization scanning technology to measure bilateral fixation via the fibers of the fovea.

Rebion Blinq's Neural Performance Scanning (NPS) technology and data management tools provide a faster, more efficient and safer way to scan children for Micro-Strabismus and Amblyopia, making early intervention and treatment more widely accessible than ever before.

Unlike other screening devices, our propriety Neural Performance Scanning (NPS) technology provides an instant and objective Pass/Refer readout based on actual brain function, not just risk factors. Improving outcomes, minimizing costly over-referrals and reducing care costs by enabling early intervention and tracking treatment progress.

The Blinq Advantage

- Blinq reduces costly over-referrals by 70% versus ARF screening.
- Blinq is 97% sensitive at detecting actual disease while ARF methods generally yield only 85% sensitivity at detecting the less rigorous metric of risk factors for disease.
- Blinq screening may be reimbursable under category III CPT code 07X6T “retinal polarization scan, ocular screening with on-site automated results, bilateral”.

About Blinq

Blinq is an evidence-based approach that addresses the objective of amblyopia screening initiatives.

Specifications

Screening distance: ~14 inches
Capture time: ~3 seconds

Blinq is indicated for use in children ages 2 to 8 under the guidance of a licensed healthcare practitioner.

Easy to Implement

Ergonomically designed for portable screening where children congregate	Ambidextrous orb design is easy to hold and unassuming to patients	Captivating target challenges patient’s visual function

Empirical Results

- Definitive “pass” and “refer” output for amblyopia, including **refractive amblyopia, micro-strabismus and strabismus.**
- Eliminates interpretation of confounding data.

Modern Application

- Blinq is designed to meet today’s screening needs.
- Encrypted data enables screening programs to remain HIPAA compliant and secure patient privacy.
- Intuitive data management applications on the device and tandem web-based tools.
- Wirelessly “push” patient lists to Blinq and “pull” screening results, eliminating the paper-trail and floating USB sticks.

Blinq® Rebion®
THE WINDOW TO THE BRAIN

Rebion®

THE WINDOW TO THE BRAIN

REBION.CO

877-499-9966

About Rebion:

Based on years of research and trials at major medical institutions, Rebion has harnessed the breakthrough **Neural Performance Scanning** (NPS) to precisely measure signal patterns that return from the brain, instantly determining if faulty signal processing is present. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible.

The company was founded by David Hunter, MD PhD, Ophthalmologist-in-Chief at Boston Children's Hospital and FDA cleared in 2016. After more than 15 years of R&D and clinical testing, Dr. Hunter co-developed this technology with Johns Hopkins and Harvard. Patients can now be confidently referred for further diagnosis and treatment, improving health outcomes and reducing treatment costs.

Rebion provides a **"Window to the Brain"** to identify and help manage life-altering conditions that manifest from **functional impairment in the brain.**

"There is something terribly wrong with the status quo when half of the children with amblyopia go undetected and untreated before school age."

David G Hunter MD PhD